FBXO11

Protein levels increase during G1 and S phases to decline as cells progress through G2 to enter in G1 phase of the next cell cycle.

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6, SNAI1 and PRDM1/BLIMP1 (PubMed:17098746, PubMed:22113614, PubMed:23478441, PubMed:23478445, PubMed:23892434, PubMed:24613396, PubMed:24968003, PubMed:25827072, PubMed:29059170). The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal center B-cells terminal differentiation toward memory B-cells and plasma cells (PubMed:22113614). The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signaling, cell migration and the timing of the cell-cycle progression and exit (PubMed:23478441, PubMed:23478445). The SCF(FBXO11) complex also catalyzes ubiquitination and degradation of GSK3B-phosphorylated SNAI1 (PubMed:25827072, PubMed:29059170). Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity (PubMed:17098746). Plays a role in the regulatiom of erythropoiesis but not myelopoiesis or megakaryopoiesis (PubMed:33156908). Mechanistically, activates erythroid genes by mediating the degradation of BAHD1, a heterochromatin-associated protein that recruits corepressors to H3K27me3 marks (PubMed:33156908). Participates in macrophage cell death and inflammation in response to bacterial toxins by regulating the expression of complement 5a receptor 1/C5AR1 and IL-1beta (PubMed:33156908). Acts as a critical regulator to determine the level of MHC-II by mediating the recognition of degron at the P/S/T domain of CIITA leading to its ubiquitination and subsequent degradation via the proteasome (PubMed:37279268). Participates in the antiviral repsonse by initiating the activation of TBK1-IRF3-IFN-I axis (PubMed:36897010). Mediates the 'Lys-63'-linked ubiquitination of TRAF3 to strengthen the interaction between TRAF3 and TBK1 (PubMed:36897010).

Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities

IDDFBA

An autosomal dominant developmental disorder with variable manifestations and onset in infancy or first years of life. Clinical features include intellectual disability, speech delay, hyperkinetic disorder, hyperactivity, seizures, pre- and postnatal growth retardation, microcephaly, and facial dysmorphism.

None

The disease is caused by variants affecting the gene represented in this entry.

Defects in FBXO11 may be a cause of diffuse large B-cell lymphoma by allowing the accumulation of BCL6, an oncoprotein that has a critical role in lymphomas.

Protein modification; protein ubiquitination.

Isoform 5 is expressed in keratinocytes, fibroblasts and melanocytes.

• Nucleus
• Chromosome

FBX11, PRMT9, VIT1, UG063H01, FBXO11, F-box only protein 11, Protein arginine N-methyltransferase 9, Vitiligo-associated protein 1, VIT-1

• entrezGene:80204
• omim:607871
• swissprot:Q86XK2

Proteins

Oncology

103585Da